In its Q1 2026 10-Q filing, Summit Therapeutics announced a pivotal FDA PDUFA date of November 14, 2026 for ivonescimab’s Biologics License Application, following strong Phase III trial results. Ivonescimab's innovative bispecific antibody mechanism targets NSCLC and colorectal cancer by dual inhibition of PD-1 and VEGF pathways, positioning it distinctively in oncology therapeutics. Despite promising clinical momentum and extensive global licensing from Akeso, Summit faces significant financial challenges with limited working capital and substantial going-concern risks. Upcoming clinical milestones and regulatory decisions will be crucial to validate the growth potential amid capital dependency.